Ex vivo studies using T cells from COVID-19 patients have demonstrated that PD-1 blockade reverses the increase in expression of the positive costimulatory marker OX40 in the CD8+ T cell fraction observed in patients who have recovered from COVID-19. The gene discussed is CD8A; the disease is COVID-19.